Protalix BioTherapeutics (NYSE:PLX) & Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Critical Analysis

Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Get Free Report) and Protalix BioTherapeutics (NYSE:PLX – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Analyst Ratings

This is a breakdown of recent recommendations for Swedish Orphan Biovitrum and Protalix BioTherapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Swedish Orphan Biovitrum 0 3 5 0 2.62
Protalix BioTherapeutics 0 0 1 0 3.00

Protalix BioTherapeutics has a consensus price target of $12.00, suggesting a potential upside of 306.09%. Given Protalix BioTherapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Swedish Orphan Biovitrum.

Volatility and Risk

Swedish Orphan Biovitrum has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500.

Valuation & Earnings

This table compares Swedish Orphan Biovitrum and Protalix BioTherapeutics”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Swedish Orphan Biovitrum $2.89 billion 6.30 $48.85 million $2.01 25.40
Protalix BioTherapeutics $84.69 million 2.94 $8.31 million $0.25 11.82

Swedish Orphan Biovitrum has higher revenue and earnings than Protalix BioTherapeutics. Protalix BioTherapeutics is trading at a lower price-to-earnings ratio than Swedish Orphan Biovitrum, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Swedish Orphan Biovitrum and Protalix BioTherapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Swedish Orphan Biovitrum 20.67% 17.92% 9.30%
Protalix BioTherapeutics -21.03% -30.89% -11.74%

Institutional & Insider Ownership

16.5% of Protalix BioTherapeutics shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Swedish Orphan Biovitrum beats Protalix BioTherapeutics on 10 of the 14 factors compared between the two stocks.

About Swedish Orphan Biovitrum

(Get Free Report)

Swedish Orphan Biovitrum AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options. Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate.

About Protalix BioTherapeutics

(Get Free Report)

Protalix BioTherapeutics is an Israel-based biopharmaceutical company that develops and manufactures recombinant therapeutic proteins using its proprietary plant-cell expression system, ProCellEx. The company focuses on treatments for rare and chronic diseases and was founded in 1993. Its products include Elelyso (taliglucerase alfa), an enzyme replacement therapy for Gaucher disease, and Elfabrio (pegunigalsidase alfa), an enzyme replacement therapy for Fabry disease. Protalix developed Elfabrio in collaboration with Chiesi Global Rare Diseases; commercialization and distribution are handled through partner arrangements in multiple markets.

Receive News & Ratings for Swedish Orphan Biovitrum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum and related companies with MarketBeat.com's FREE daily email newsletter.